26 нояб. 2024 г. · Medicare is able to negotiate directly with drug companies to improve access to some of the costliest single-source brand-name Medicare Part B and Part D drugs.

19 нояб. 2024 г. · For 2027, 15 Medicare Part D drugs will be selected for price negotiation (or up to 15 if fewer drugs qualify for selection based on the ...

2 окт. 2024 г. · Any MFPs that are agreed upon during this second cycle of negotiations will be effective in 2027. The draft guidance also sought public comment ...

2 окт. 2024 г. · Today, HHS is releasing final guidance for the second cycle of the Inflation Reduction Act's Medicare Drug Price Negotiation Program.

8 окт. 2024 г. · Draft Guidance: Consistent with the IPAY 2026 Final Guidance, CMS reiterated that it would negotiate a single MFP, subject to a single MFP ...

10 окт. 2024 г. · ... Drug Price Negotiation Program and manufacturer effectuation of the maximum fair price in 2026 and 2027 for the implementation of the Inflation.

23 авг. 2024 г. · Novo Nordisk, Pfizer, GSK drugs likely to be in 2027 Medicare negotiations · Most drugs already discounted, limited impact seen on Big Pharma ...

4 окт. 2024 г. · The negotiated prices for the first 10 drugs from the initial cycle will take effect starting January 1, 2026, marking the beginning of CMS's ...

GAO found that this rule provides CMS's final guidance of the second cycle of the Medicare Drug Price Negotiation Program and manufacturer effectuation of the ...

3 окт. 2024 г. · CMS will announce the next round, this time selecting 15 drugs, by Feb. 1. Those prices will be effective starting Jan. 1, 2027. Related. CMS: ...